Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe ...
Sanofi (ENXTPA:SAN) secures European Commission approval to expand Dupixent use to children with chronic spontaneous urticaria. The company becomes the Canadian market authorization holder for ...
In the U.S., the supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in certain children aged 2 to 11 years with CSU. Dupixent is currently approved for CSU in ...
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
Dupixent is back in the driver’s seat, reclaiming the top spot for ad impressions among Rx and over-the-counter (OTC) brands in May. The eczema and asthma drug from Sanofi and Regeneron had an ...
For the second consecutive month, Dupixent finished as the leader among the top 10 Rx and over-the-counter brands. The eczema and asthma drug from Sanofi and Regeneron had an impressions share of ...
Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...
Sanofi and Regeneron’s Dupixent has scored in a second phase 3 study in chronic obstructive pulmonary disease (COPD), setting up the monoclonal antibody to become the first biologic to treat the lung ...
Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results